HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.

Abstract
It is well documented that the mitogen-activated protein kinase pathway plays a pivotal role in rats with 6-hydroxydopamine (6-OHDA)-induced unilateral lesion in the nigrostriatal system. Our recent studies have shown that mixed-lineage kinase 3 (MLK3) and apoptosis-inducing kinase 1 (ASK1) are all involved in neuronal cell death induced by ischemia, which is mediated by the MLK3/c-Jun NH2-terminal kinase 3 (JNK3) and ASK1/JNK signaling pathway. To investigate whether these pathways are correlated with 6-OHDA-induced lesion as well, we examined the phosphorylation of MLK3, ASK1, and JNK3 in 6-OHDA rats. The results showed that both MLK3 and ASK1 could activate JNK3 and then subsequently enhance the neuronal death through its downstream pathways (i.e., nuclear and non-nuclear pathway). K252a have wide-range effects including Trk inhibition, MLK3 inhibition, and activation of phosphatidylinositol 3 kinase and mitogen-activated protein kinase kinase signaling pathways through interactions with distinct targets and is a well known neuroprotective compound. We found that K252a could protect dopaminergic neurons against cell program death induced by 6-OHDA lesion, and the phenotypes of 6-OHDA rat model treated with K252a were partial rescued. The inhibition of K252a on the activation of MLK3/JNK3 and ASK1/JNK3 provided a link between 6-OHDA lesion and stress-activated kinases. It suggested that both proapoptotic MLK3/JNK3 and ASK1/JNK3 cascade may play an important role in dopaminergic neuronal death in 6-OHDA insult. Thus, the JNK3 signaling may eventually emerge as a prime target for novel therapeutic approaches to treatment of Parkinson disease, and K252a may serve as a potential and important neuroprotectant in therapeutic aspect in Parkinson disease.
AuthorsJing Pan, Gang Wang, Hong-Qi Yang, Zhen Hong, Qin Xiao, Ru-Jing Ren, Hai-Yan Zhou, Li Bai, Sheng-Di Chen
JournalMolecular pharmacology (Mol Pharmacol) Vol. 72 Issue 6 Pg. 1607-18 (Dec 2007) ISSN: 1521-0111 [Electronic] United States
PMID17855652 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carbazoles
  • Enzyme Inhibitors
  • Indole Alkaloids
  • Oxidopamine
  • staurosporine aglycone
  • Mitogen-Activated Protein Kinase 10
  • MAP Kinase Kinase Kinases
  • mitogen-activated protein kinase kinase kinase 11
  • Dopamine
Topics
  • Animals
  • Apoptosis (drug effects, physiology)
  • Carbazoles (pharmacology)
  • Cell Death (drug effects, physiology)
  • Dopamine (metabolism, physiology)
  • Enzyme Inhibitors (pharmacology)
  • Female
  • Indole Alkaloids (pharmacology)
  • MAP Kinase Kinase Kinases (antagonists & inhibitors, physiology)
  • Mitogen-Activated Protein Kinase 10 (antagonists & inhibitors, metabolism)
  • Oxidopamine (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction (drug effects, physiology)
  • Substantia Nigra (drug effects, enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: